Key terms
About BOLT
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BOLT news
Mar 25
11:05am ET
Bolt Biotherapeutics: A Strong Buy on Clinical Progress and Financial Stability
Mar 24
9:27pm ET
Bolt Biotherapeutics’ Promising Trajectory in Immuno-Oncology: A Strong Buy Recommendation
Mar 22
6:21am ET
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Intuitive Surgical (ISRG) and Bolt Biotherapeutics (BOLT)
Mar 21
4:06pm ET
Bolt Biotherapeutics reports Q4 EPS (47c), consensus (48c)
No recent news articles are available for BOLT
No recent press releases are available for BOLT
BOLT Financials
Key terms
Ad Feedback
BOLT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BOLT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
